Arcellx (ACLX) Financial Analysis & Valuation | Quarter Chart
Arcellx (ACLX)
ACLXPrice: $115.07
Fair Value: 🔒
🔒score
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with re... more
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunot... more
Description
Shares
| Market Cap | $6.73B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Rami Elghandour |
| IPO Date | 2022-02-04 | CAGR | — |
| Employees | 163 | Website | arcellx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ACLX chart loading...
Fundamentals
Technicals
| Enterprise Value | $5.52B | P/E Ratio | -28.27 |
| Forward P/E | -77.74 | PEG Ratio | — |
| P/S Ratio | 0.01 | P/B Ratio | 0.01 |
| P/CF Ratio | -0.01 | P/FCF Ratio | -0.01 |
| EPS | $-4.07 | EPS Growth 1Y | 425.33% |
| EPS Growth 3Y | -23.35% | EPS Growth 5Y | — |
| Revenue Growth 1Y | -80.14% | Gross Margin | 0.97% |
| Operating Margin | -3.76% | Profit Margin | -3.3% |
| ROE | -0.43% | ROA | -0.3% |
| ROCE | -0.43% | Current Ratio | 3.81 |
| Quick Ratio | 3.81 | Cash Ratio | 0.51 |
| Debt/Equity | 0.13 | Interest Coverage | -1611.97 |
| Altman Z Score | 16.41 | Piotroski Score | 1 |